PMID- 31388422
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 1828-695X (Print)
IS  - 2049-6958 (Electronic)
IS  - 1828-695X (Linking)
VI  - 14
DP  - 2019
TI  - Efficacy and safety profile of doxofylline compared to theophylline in asthma: a 
      meta-analysis.
PG  - 25
LID - 10.1186/s40248-019-0189-0 [doi]
LID - 25
AB  - BACKGROUND: Oral methylxanthines are effective drugs for the treatment of chronic 
      obstructive respiratory disorders. The novel methylxanthine doxofylline, that has 
      bronchodilator and anti-inflammatory activities, is not affected by the major 
      drawback of theophylline. Nowadays large-scale quantitative synthesis comparing 
      the efficacy and safety profile of doxofylline vs. theophylline in the treatment 
      of asthma is still lacking. Therefore, we performed a quantitative synthesis to 
      compare the efficacy/safety profile of doxofylline and theophylline in asthma. 
      METHODS: A pairwise and network meta-analyses were performed to assess the impact 
      of doxofylline vs. theophylline and placebo on the change in asthma events, risk 
      of adverse events (AEs), forced expiratory volume in 1 s (FEV(1)), and salbutamol 
      use. RESULTS: Data obtained from 696 asthmatic patients were extracted from 4 
      randomized controlled trials published between 2015 and 2018. Doxofylline was 
      significantly (P < 0.05) more effective than theophylline in reducing the daily 
      asthma events (mean difference - 0.14, 95%CI -0.27 - 0.00) and risk of AEs 
      (relative risk 0.76, 95%CI 0.59-0.99). Doxofylline was as effective as 
      theophylline in improving FEV(1), and a trend of superiority (P = 0.058) was 
      detected for doxofylline over theophylline with respect to the reduction in the 
      use of salbutamol as rescue medication. The rank of effectiveness was 
      doxofylline>theophylline> > placebo, and the rank of safety was 
      placebo>doxofylline> > theophylline. CONCLUSIONS: Doxofylline is an effective and 
      safe methylxanthine for the treatment of asthma, with an efficacy/safety profile 
      greater than that of theophylline. TRIAL REGISTRATION: Meta-analysis 
      registration: CRD42019119849.
FAU - Rogliani, Paola
AU  - Rogliani P
AD  - 1Unit of Respiratory Medicine, Department of Experimental Medicine, University of 
      Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy. ISNI: 0000 0001 2300 
      0941. GRID: grid.6530.0
FAU - Calzetta, Luigino
AU  - Calzetta L
AUID- ORCID: 0000-0003-0456-069X
AD  - 1Unit of Respiratory Medicine, Department of Experimental Medicine, University of 
      Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy. ISNI: 0000 0001 2300 
      0941. GRID: grid.6530.0
FAU - Ora, Josuel
AU  - Ora J
AD  - 2Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, 
      Italy. GRID: grid.413009.f
FAU - Cazzola, Mario
AU  - Cazzola M
AD  - 1Unit of Respiratory Medicine, Department of Experimental Medicine, University of 
      Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy. ISNI: 0000 0001 2300 
      0941. GRID: grid.6530.0
FAU - Matera, Maria Gabriella
AU  - Matera MG
AD  - 3Unit of Pharmacology, Department of Experimental Medicine, University of 
      Campania "Luigi Vanvitelli", Naples, Italy. ISNI: 0000 0001 2200 8888. GRID: 
      grid.9841.4
LA  - eng
PT  - Journal Article
DEP - 20190803
PL  - Italy
TA  - Multidiscip Respir Med
JT  - Multidisciplinary respiratory medicine
JID - 101477642
PMC - PMC6679461
OTO - NOTNLM
OT  - Asthma
OT  - Doxofylline
OT  - Meta-analysis
OT  - Theophylline
COIS- Competing interestsPR has participated as an advisor in scientific meetings the 
      sponsorship of ABC Farmaceutici; LC has participated as an advisor in scientific 
      meetings the sponsorship of ABC Farmaceutici; he is or has been a consultant to 
      ABC Farmaceutici; JO has no competing interests; MGM has participated as an 
      advisor in scientific meetings the sponsorship of ABC Farmaceutici; MC has 
      participated as an advisor in scientific meetings the sponsorship of ABC 
      Farmaceutici; he is or has been a consultant to ABC Farmaceutici. MC is a member 
      of the Editorial Board of Multidisciplinary Respiratory Medicine.
EDAT- 2019/08/08 06:00
MHDA- 2019/08/08 06:01
PMCR- 2019/08/03
CRDT- 2019/08/08 06:00
PHST- 2019/02/22 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/08/08 06:00 [entrez]
PHST- 2019/08/08 06:00 [pubmed]
PHST- 2019/08/08 06:01 [medline]
PHST- 2019/08/03 00:00 [pmc-release]
AID - 189 [pii]
AID - 10.1186/s40248-019-0189-0 [doi]
PST - epublish
SO  - Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. 
      eCollection 2019.